Peptonic Medical

The agreement means that Peptonic gets the right to sell Prima Lab's self-test for urinary tract infections under its own brand VagiVital^® in Sweden, with a planned launch at the end of 2023.

"Urinary tract infections affect 40% of all women of all ages at some point in their lives, with many experiencing recurrent infections. Adding another high-quality self-test to the reference market Sweden will be another valuable step in building a leading portfolio of clinically proven self-care products consistent with the principle of diagnose, treat and prevent", says Erik Sundquist, CEO of Peptonic.

Prima Lab is a Swiss medical technology company with a specific focus on self-tests for women's health. The company conducts its own research and development and sells its products in more than thirty countries around the world. Prima Lab's self-test for urinary tract infections has a high level of precision as it measures on four parameters - blood, protein, leukocytes and nitrites - unlike most other products that measure only two or three parameters.

Prima Lab is already a strategic partner to Peptonic as Prima distributes Peptonics patented test for amniocentesis exclusively in a number of selected markets in Europe.

"To deepen the collaboration with Prima Lab, which is a leading player in self-tests for women's health, we see as a very valuable step as we continue to build our portfolio", says Erik Sundquist.

"Peptonic is a growing and important player in women's health. Accordingly, we see the introduction of our self-test for urinary tract infections on the Swedish market as very valuable for our continued expansion", says Prima Lab's CEO and founder Federico Roveda.